publication date: Dec. 19, 2010

In this issue: 

A message from NCI: “We deeply regret the need to eliminate this program.” AP4 applicants and corporate partners spent years, money, before NCI pulled the plug on novel public-private partnerships. Von Eschenbach called AP4 “a new paradigm” for drug development. NCI Executive Committee “prioritized” programs.

Also NSABP’s STAR trial finds raloxifene equivalent to tamoxifen for breast cancer risk reduction.

Download (PDF 726KB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.